International

Pharma patent deal-making may be back with a bang

Following a spate of licensing deals, high-value life sciences M&A now seems to be back in business after a pandemic-induced pause

Pharma patent deal-making may be back with a bang
The top 10 takeaways from this year’s Global Innovation Index
9 Sep 2020

The top 10 takeaways from this year’s Global Innovation Index

The latest edition of the annual WIPO publication reveals that Europe and North America still lead despite rising innovation levels in Asia

US-India trade negotiations could prove an IP turning point
1 Sep 2020

US-India trade negotiations could prove an IP turning point

A deal – potentially including reforms to controversial Indian patent laws – is said to be almost agreed with time running out before American presidential elections

Latest

View all
27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

20 Aug 2020

Potential breakthrough covid vaccine faces even greater IP uncertainties

Both private and state entities may own a slice of Moderna’s lucrative late-stage treatment Read more

18 Aug 2020

AI-assisted covid-19 inventions raised new IP discussions, says scientist behind recent breakthroughs

IAM speaks to University of Michigan’s Professor Timothy Cernak about patent and licensing issues raised by recent chemical synthesis innovations Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

Designs

View all
20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Finance

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

13 Feb 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco Read more

Frand/SEPS

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

28 Feb 2020

The US has a mountain to climb in 5G network equipment

Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Law & Policy

View all
12 Aug 2020

Reporting serious allegations made against WIPO director general was not fake news, it was essential

The outgoing WIPO director insists that full transparency should be a key concern of the new head Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

26 May 2020

WHO covid-19 IP pool launches this week without strong pharma support

Open and global sharing of patents, data and know-how is seen as a step too far by many life sciences innovators Read more

21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

Litigation

View all
4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

15 Jun 2020

The University of California builds its patent portfolio, but not its royalty returns

The world-renowned school has seen its licensing income stall and that could force it to take a more aggressive line in securing ROI Read more

20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

Market Developments

View all
4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

22 Jul 2020

Diagnostics dominate med-tech asset sales amidst pandemic disruption

The current crisis has affected M&A in the sector, but older trends will shape longer-term deal-making Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

14 Jul 2020

Today’s academics are far more IP savvy, Imperial tech transfer head states

“We have a much more knowledgeable, skilled and entrepreneurial client base these days,” says Andrew Tingey Read more

Non-Practising Entities

View all
20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

14 Jul 2020

Today’s academics are far more IP savvy, Imperial tech transfer head states

“We have a much more knowledgeable, skilled and entrepreneurial client base these days,” says Andrew Tingey Read more

2 Jun 2020

MPEG LA builds new biotech licensing programmes and remains hopeful on CRISPR pool

Trend suggests a growing similarity between patent monetisation models in the life sciences and high-tech sectors Read more

21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

Patent Pools

View all
20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation Read more

2 Jun 2020

MPEG LA builds new biotech licensing programmes and remains hopeful on CRISPR pool

Trend suggests a growing similarity between patent monetisation models in the life sciences and high-tech sectors Read more

Patents Law

View all
12 Aug 2020

Reporting serious allegations made against WIPO director general was not fake news, it was essential

The outgoing WIPO director insists that full transparency should be a key concern of the new head Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

22 Jul 2020

Diagnostics dominate med-tech asset sales amidst pandemic disruption

The current crisis has affected M&A in the sector, but older trends will shape longer-term deal-making Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

Strategy

View all
4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

22 Jul 2020

Diagnostics dominate med-tech asset sales amidst pandemic disruption

The current crisis has affected M&A in the sector, but older trends will shape longer-term deal-making Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

14 Jul 2020

Today’s academics are far more IP savvy, Imperial tech transfer head states

“We have a much more knowledgeable, skilled and entrepreneurial client base these days,” says Andrew Tingey Read more

Technology Licensing

View all
4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

22 Jul 2020

Diagnostics dominate med-tech asset sales amidst pandemic disruption

The current crisis has affected M&A in the sector, but older trends will shape longer-term deal-making Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

14 Jul 2020

Today’s academics are far more IP savvy, Imperial tech transfer head states

“We have a much more knowledgeable, skilled and entrepreneurial client base these days,” says Andrew Tingey Read more

Trade Secrets

View all
23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation Read more

2 Jun 2020

MPEG LA builds new biotech licensing programmes and remains hopeful on CRISPR pool

Trend suggests a growing similarity between patent monetisation models in the life sciences and high-tech sectors Read more

21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

Valuation

View all
22 Jul 2020

Diagnostics dominate med-tech asset sales amidst pandemic disruption

The current crisis has affected M&A in the sector, but older trends will shape longer-term deal-making Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

14 Jul 2020

Today’s academics are far more IP savvy, Imperial tech transfer head states

“We have a much more knowledgeable, skilled and entrepreneurial client base these days,” says Andrew Tingey Read more

23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

Find an expert

Susanne T Jones
Managing Partner
Mclean VA, United States
Jones Robb PLLC